What's behind Monopar Therapeutics's latest stock pullback?

What's behind Monopar Therapeutics's latest stock pullback?
Monopar Therapeutics drops 4.8% today

Monopar Therapeutics Inc. (MNPR) dropped 4.8% today as technical overbought conditions triggered heavy intraday selling pressure. The pullback is supported by the stock's proximity to major resistance at $118.38, with the move testing underlying momentum after a broad run above all key moving averages.

MNPR price prediction
24H 1.21%
$72.9425
48H 3.52%
$74.61
7D 3.49%
$74.5825
1M 1.67%
$73.27
3M -20.38%
$57.3838
6M -32.96%
$48.3126
12M -5.94%
$67.7895
Current price: $72.07 -0.6100 0.84%
Closed 11/13
Daily range 68.6600 Arrow from to Icon 73.6350
Weekly range 67.2200 Arrow from to Icon 75.2600
Loading...

Highlights

  • Monopar Therapeutics stock trades above all short-, medium-, and long-term moving averages, showing sustained bullish momentum.
  • Overbought technical signals are widespread, with the stock down 4.8% to $118.285 and trading near the session low after a downside gap.
  • Projected five-session range is $109.81 to $126.76, with an 80% probability of an upward move and resistance at $118.38.
Anton Kharitonov, expert at Traders Union, sees Monopar Therapeutics facing increased risk after a sharp drop of 4.8% paired with clear overbought signals. He notes that the current structure is technically bullish, but the stretched RSI, Stochastic, and CCI are red flags, especially with price stalling at major resistance of $118.38. No supportive corporate news means current momentum is speculative and vulnerable to profit-taking. Kharitonov believes the lack of fresh fundamental catalysts amplifies downside risk as momentum fades. He warns, "With buyers fatigued and momentum indicators peaking, I expect volatility and urge caution near these levels."
Viktoras Karapetjanc, expert at Traders Union, remains upbeat about Monopar Therapeutics’ technical setup. He highlights that the bullish structure remains intact since the price is still above all key moving averages, and strong momentum indicators signal further growth potential. Karapetjanc sees this pullback as a routine consolidation after a powerful rally, with limited downside risk as long as support at $114.1723 holds. He notes increased buyer control, as confirmed by BBP and other trend signals. "The overall market offers multiple setups here, and I expect a breakout above $118.38 could drive a rally toward $126.76 in the coming sessions," he says.
Sholanke Dele, market strategist, approaches Monopar Therapeutics with caution following today's pullback. He sees the absence of supportive news as a weakness that could undermine confidence in the current move. Dele views overbought technicals and a price reversal as signs that recent optimism may be unsustainable. "Without new catalysts or positive news flow, I am skeptical of the stock maintaining these levels in the near term," Dele says.
Monopar Therapeutics asset chart
Monopar Therapeutics price dynamics. Source: TradingView.

Bullish momentum evident as price tests overbought levels

Monopar Therapeutics is trading above all key moving averages: MA-20 ($114.1723), MA-50 ($98.7343), and MA-200 ($73.2476). This alignment signals ongoing bullish momentum across short-, medium-, and long-term time frames, with the MA-50 versus MA-200 setup also confirming a bullish trend structure. The immediate technical ceiling is at $118.38, while the near-term floor sits at $114.1723. The Ichimoku Kijun at $111.375 is positioned as underlying support beneath both the price and moving averages. Momentum remains robust, with both the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) indicating strong buying pressure. The Relative Strength Index (RSI) is elevated at 66.565, with Stochastic RSI at 94.2482 and Commodity Channel Index (CCI) at 132.3842, all pointing to overbought conditions. Bull/Bear Power (BBP) at 8.2105 confirms buyers are firmly in control, accompanied by an overbought warning. The Awesome Oscillator (AO) is neutral. The stock is down to $118.285, slipping 4.8% today after opening with a downside gap of about $1.65, or 1.33%. The current price is near the session low, and intraday volatility stands at 3.56%. Early pressure after the open aligns with overbought signals, suggesting intraday fatigue among buyers.

Earlier, analysts noted that Monopar Therapeutics was sustaining strong bullish momentum but faced overbought technical conditions that could trigger a period of consolidation. The latest session’s intraday pullback amid elevated volatility reinforces these signals, highlighting $118.38 as a critical breakout level for potential renewed upside in the days ahead.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.